NASDAQ · YDESW

YD Bio Limited

$0.24 +$0.01 (+5.56%) 1D Market open

Key Metrics

$16.21M
Market cap
P/E · TTM
$596.82K
Revenue · TTM
−$8.31M
Net income
EPS · TTM $-0.12
Dividend yield
Free cash flow −$8.04M
Beta · 1Y 2.15
EBITDA · TTM −$8.30M
Gross margin 28.1%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 23
    From its Feb 2 high, the share price fell 76%.

    Peak close $0.95 on Feb 2; trough close $0.23 on Jul 23. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -76%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 6
    The stock moved +23.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 6
  • Jun 22
    The stock moved +43.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 22

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value$10.21M
Shares outstanding
52-wk range$0.20 – $2.85
Avg volume · 20D34.4K
Net cash $6.00M
Book value / share$-0.04
ExchangeNASDAQ
About YD Bio Limited
IPO dateAug 29, 2025
Employees15

YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S27.15
P/FCF
EV/EBITDA
EV/Sales17.10
Graham №

Profitability

Gross 28.1%
Operating -1,392.9%
Net -1,392.6%
FCF -1,346.6%
ROE / ROIC 291.0% · 93.8%

Financial Health

Current ratio5.88
Quick ratio4.74
Debt / equity0.00
Debt / EBITDA 0.00
Net cash $6.00M
Working capital$8.03M

Cash Flow · TTM

Operating CF −$6.60M
Capex −$1.44M
Free cash flow −$8.04M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

Needs two fiscal years of filings

Altman Z-Score

-1.7
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-06-30 · computed by TickerWolf from SEC filings